Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Developments and Current Treatment Standards in Cervical Cancer

Developments and Current Treatment Standards in Cervical Cancer The prognosis of patients with cervical cancer has improved dramatically in the last 20 years due to the success of systematic screening programs; however, the disease remains a major health problem worldwide. Patients with advanced, recurrent or metastatic disease still have a poor prognosis. Over the last century, radical surgery and radiotherapy have been used to improve survival rates in patients with primary cervical cancer. Both methods have been extensively modified over the years; however, neither improvements in surgical therapy (e.g. radical lymph node dissection) nor modified radiotherapy methods (e.g. neutron irradiation, hyperthermia, interstitial brachytherapy) have significantly decreased the mortality rates. Recently, cooperative clinical trials have demonstrated the superiority of multimodality strategies for patients with high-risk cervical cancer. In these studies, chemotherapy has been integrated into primary therapy; results have shown the most significant improvement of locally advanced disease in more than three decades. The introduction of modern surgical techniques, such as laparoscopic lymphonodectomy and radical pelvic exenteration, are new developments that will change the treatment of cervical cancer in the near future. This review summarizes different aspects of cervical cancer therapy, with emphasis on invasive disease, and provides a perspective on developments which may improve both local and systemic treatment of the disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Developments and Current Treatment Standards in Cervical Cancer

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/developments-and-current-treatment-standards-in-cervical-cancer-fr3sWdUPcx
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504060-00004
Publisher site
See Article on Publisher Site

Abstract

The prognosis of patients with cervical cancer has improved dramatically in the last 20 years due to the success of systematic screening programs; however, the disease remains a major health problem worldwide. Patients with advanced, recurrent or metastatic disease still have a poor prognosis. Over the last century, radical surgery and radiotherapy have been used to improve survival rates in patients with primary cervical cancer. Both methods have been extensively modified over the years; however, neither improvements in surgical therapy (e.g. radical lymph node dissection) nor modified radiotherapy methods (e.g. neutron irradiation, hyperthermia, interstitial brachytherapy) have significantly decreased the mortality rates. Recently, cooperative clinical trials have demonstrated the superiority of multimodality strategies for patients with high-risk cervical cancer. In these studies, chemotherapy has been integrated into primary therapy; results have shown the most significant improvement of locally advanced disease in more than three decades. The introduction of modern surgical techniques, such as laparoscopic lymphonodectomy and radical pelvic exenteration, are new developments that will change the treatment of cervical cancer in the near future. This review summarizes different aspects of cervical cancer therapy, with emphasis on invasive disease, and provides a perspective on developments which may improve both local and systemic treatment of the disease.

Journal

American Journal of Cancer – Springer Journals

Published: Aug 9, 2012

References

  • Global cancer statistics
    Parkin, D.M.; Pisani, P.; Ferlay, J.
  • The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study
    Smith, H.O.; Tiffany, M.F.; Quails, C.R.
  • Cancer statistics, 2003
    Jemal, A.; Murray, T.; Samuels, A.
  • Principles and practice of gynecologic oncology group
    Perez, C.; Kurman, R.; Stehman, F.
  • Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study
    Kumar, L.; Kaushal, R.; Nandy, M.
  • A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix
    Souhami, L.; Gil, R.A.; Allan, S.E.
  • A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastases
    Tattersall, M.H.N.; Corazon, R.; Coppleson, M.
  • Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group)
    Chiara, S.; Bruzzone, M.; Merlini, L.
  • Concomitant and neoadjuvant chemotherapy in conjunction with radiotherapy in the management of locally advanced cervical cancer
    Tattersall, M.H.
  • Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: a randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
    Sundfor, K.; Trope, C.G.; Hogberg, T.
  • Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a randomized phase III randomized trial
    Leborgne, F.; Leborgne, J.H.; Doldan, R.
  • A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluoruracil in locally advanced cervical cancer
    Thomas, G.; Dembo, A.; Ackerman, I.
  • Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival?
    Finan, M.A.; DeCesare, S.; Fiorica, J.V.
  • Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma
    Keys, H.M.; Bundy, B.N.; Stehman, F.B.
  • A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study
    Whitney, C.W.; Sause, W.; Bundy, B.N.
  • Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer
    Rose, P.G.; Bundy, B.N.; Watkins, E.B.
  • Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high risk cervical cancer
    Morris, M.; Eifel, P.J.; Grigsby, P.W.
  • Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
    Peters, W.A.; Liu, P.Y.; Barrett, R.J.
  • Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy
    Thomas, G.M.
  • The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
    Grogan, M.; Thomas, G.M.; Melamed, I.
  • Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma
    Obermair, A.; Cheuk, R.; Horwood, K.
  • The Italian gynecological consensus statement on the use of epoetin alfa in the management of anaemia
    Pecorelli, S.
  • Anemia, hypoxia and transfusion in patients with cervical cancer: a review
    Fyles, A.W.; Milosevic, M.; Pintilie, M.
  • Laparoscopy-assisted radical vaginal hysterectomy modified according to Schauta-Stoeckel
    Schneider, A.; Possover, M.; Kamprath, S.
  • Surgical management of advanced and recurrent cervical cancer
    Estape, R.; Angioli, R.
  • Clinical and histopathological factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix
    Shingleton, H.M.; Soong, S.J.; Gelder, M.
  • Palliative exenteration: what, when and why?
    Stanhope, C.R.; Symmonds, R.E.
  • Surgical management of advanced and recurrent cervical cancer
    Estape, R.; Angioli, R.
  • Pelvic exenteration in the elderly patient
    Matthews, C.M.; Morris, M.; Burke, T.W.
  • A possible new trend in the management of carcinoma of the cervix uteri
    Sardi, J.; Paola, G.; Sananes, C.
  • Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer
    Ting-Chang, C.; Chyong-Huey, L.; Ji-Hong, H.
  • Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association
    Tattersall, M.H.N.; Larvidhaya, V.; Vootiprux, V.
  • Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: a randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
    Sundfør, K.; Trope, C.G.; Hogberg, T.
  • New drugs in gynecologic oncology
    Eisenhauer, E.A.; Vermorken, J.B.
  • Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
    Francis, P.; Schneider, J.; Hann, L.
  • Phase II study of docetaxel for advanced or metastatic platinum-refractory non small-cell lung cancer
    Fosella, F.V.; Lee, J.S.; Shin, D.M.
  • Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer [abstract]
    Rein, D.T.; Kurbacher, C.M.; Breidenbach, M.
  • The bulky 6-cm barrel-shaped lesion of the cervix: primary surgery and postoperative chemoradiation
    Boronow, R.C.
  • Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Bonomi, P.; Blessing, J.A.; Stehman, F.B.
  • A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix uteri (a Gynecologic Oncology Group study)
    Arseneau, J.; Blessing, J.A.; Stehman, F.B.
  • Principles and practice of gynecologic oncology
    Stehman, F.B.; Perez, C.A.; Kurman, R.J.
  • New drugs in gynecologic oncology
    Vermorken, J.B.
  • Cervix cancer
    Brenner, D.
  • Phase II studies of bleomycin and cisplatin in advanced cervical carcinoma
    Edmondson, J.; Johnson, P.; Wieand, H.S.
  • Cervical carcinoma: a drug responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy
    Friedlander, M.; Kaye, S.; Sullivan, A.
  • Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer
    Sugiyama, T.; Nishida, T.; Hasuo, Y.
  • Cancer principles and practice of oncology
    Eifel, P.J.; Berek, J.S.; Thigpen, J.T.
  • Cisplatinum, doxorubicin, and methotrexate for recurrent cervical cancer
    Wheelock, J.; Krebs, H.; Goplerud, D.
  • Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide
    Chauvergne, J.; Heron, J.; Mayer, F.
  • A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix
    Witt, R.; Zee, J.; Burg, M.E.
  • Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group study
    Alberts, D.S.; Kronmal, R.; Baker, L.H.
  • Chemotherapy for stage IVB or recurrent cancer of the uterine cervix
    Omura, G.A.
  • Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study
    Bloss, J.D.; Blessing, J.A.; Behrens, B.C.
  • Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Moore, D.H.; Blessing, J.A.; McQuellon, R.P.